Identification of Drugs Associated with Lower Risk of Parkinson’s Disease Using a Systematic Screening Approach in a Nationwide Nested Case–Control Study

References

• Lang AE, Espay AJ. Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord. 2018;33:660–677. doi:10.1002/mds.27360
   PubMed Web of Science ®Google Scholar
• Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease - repurposed drugs and new approaches. Nat Rev Neurol. 2019;15:204–223
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Kern DM, Seabrook GR, Lovestone S. Comprehensive real-world assessment of marketed medications to guide Parkinson’s drug discovery. Clin Drug Investig. 2019;39:1067–1075. doi:10.1007/s40261-019-00830-4
   Web of Science ®Google Scholar
• Maclagan LC, Visanji NP, Cheng Y, et al. Identifying drugs with disease-modifying potential in Parkinson’s disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29:864–872. doi:10.1002/pds.5015
   Web of Science ®Google Scholar
• Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257–1272.
   PubMed Web of Science ®Google Scholar
• Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol Dis. 2011;43:364–371.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group STEADY-PD III Investigators. Isradipine versus placebo in early Parkinson disease: a randomized trial. Ann Intern Med. 2020;172:591–598. doi:10.7326/M19-2534
   PubMed Web of Science ®Google Scholar
• Surmeier DJ, Nguyen JT, Lancki N, et al. Re-analysis of the STEADY-PD II trial-evidence for slowing the progression of Parkinson’s disease. Mov Disord. 2022;37:334–342. doi:10.1002/mds.28850
   Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675.
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis. 2014;4:337–344. doi:10.3233/JPD-140364
   PubMedGoogle Scholar
• Raman SR, Man KKC, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5:824–835. doi:10.1016/S2215-0366(18)30293-1
   PubMed Web of Science ®Google Scholar
• Hentilä E, Tiihonen M, Taipale H, Hartikainen S, Tolppanen AM. Incidence of antidepressant use among community dwellers with and without Parkinson’s disease - a nationwide cohort study. BMC Geriatr. 2021;21:202. doi:10.1186/s12877-021-02145-6
   Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184. doi:10.1136/jnnp.55.3.181
   PubMed Web of Science ®Google Scholar
• Paakinaho A, Karttunen N, Koponen M, et al. Incidence of muscle relaxant use in relation to diagnosis of Parkinson’s disease. Int J Clin Pharm. 2020;42:336–340. doi:10.1007/s11096-020-01002-7
   Web of Science ®Google Scholar
• Paakinaho A, Koponen M, Tiihonen M, Kauppi M, Hartikainen S, Tolppanen AM. Disease-modifying antirheumatic drugs and risk of Parkinson disease: nested case-control study of people with rheumatoid arthritis. Neurology. 2022;98:e1273–e1281. doi:10.1212/WNL.0000000000013303
   Web of Science ®Google Scholar
• Sunnarborg K, Tiihonen M, Huovinen M, Koponen M, Hartikainen S, Tolppanen AM. Association between different diabetes medication classes and risk of Parkinson ‘s disease in people with diabetes. Pharmacoepidemiol Drug Saf. 2022;31:875–882. doi:10.1002/pds.5448
   Web of Science ®Google Scholar
• Paakinaho A, Tiihonen M, Koskela H, et al. Beta2-adrenoceptor agonists in asthma or chronic obstructive pulmonary disease and risk of Parkinson’s disease: nested case-control study. submitted.
   Google Scholar
• Mertsalmi TH, Pekkonen E, Scheperjans F. Antibiotic exposure and risk of Parkinson’s disease in Finland: a nationwide case-control study. Mov Disord. 2020;35:431–442. doi:10.1002/mds.27924
   Web of Science ®Google Scholar
• Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system — associations, mechanisms and therapeutics. Nat Rev Neurol. 2020;16:303–318. doi:10.1038/s41582-020-0344-4
   PubMed Web of Science ®Google Scholar
• Cortese M, Riise T, Engeland A, Ascherio A, Bjørnevik K. Urate and the risk of Parkinson’s disease in men and women. Parkinsonism Relat Disord. 2018;52:76–82. doi:10.1016/j.parkreldis.2018.03.026
   Web of Science ®Google Scholar
• Lai S-W, Lin C-L, Liao KF. Association between allopurinol use and Parkinson’s disease in older adults. Eur Geriatr Med. 2018;9:377–381. doi:10.1007/s41999-018-0055-1
   Web of Science ®Google Scholar
• Schernhammer E, Qiu J, Wermuth L, Lassen CF, Friis S, Ritz B. GOUT AND THE RISK OF PARKINSON’S DISEASE IN DENMARK. Eur J Epidemiol. 2013;28:359–360. doi:10.1007/s10654-013-9791-1
   Web of Science ®Google Scholar
• Gökçe Çokal B, Yurtdaş M, Keskin Güler S, et al. Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson’s disease. Neurol Sci. 2017;38:425–431. doi:10.1007/s10072-016-2782-8
   Web of Science ®Google Scholar
• Pakpoor J, Seminog OO, Ramagopalan SV, Goldacre MJ. Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies. BMC Neurol. 2015;15:16. doi:10.1186/s12883-015-0273-9
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Srivali N, Thongprayoon C. Gout is not associated with a lower risk of Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2015;21:1238–1242. doi:10.1016/j.parkreldis.2015.08.030
   Web of Science ®Google Scholar
• Alonso A, Rodríguez LAG, Logroscino G, Hernán MA. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69:1696–1700.
   PubMed Web of Science ®Google Scholar
• De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Care Res. 2008;59:1549–1554. doi:10.1002/art.24193
   Web of Science ®Google Scholar
• Singh JA, Cleveland JD. Gout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data. BMC Neurol. 2019;19:4. doi:10.1186/s12883-018-1234-x
   Web of Science ®Google Scholar
• Kim JH, Choi IA, Kim A, Kang G. Clinical association between gout and Parkinson’s disease: a nationwide population-based cohort study in Korea. Medicina. 2021;57:1292. doi:10.3390/medicina57121292
   Web of Science ®Google Scholar
• L-Y H, Yang AC, Lee S-C, et al. Risk of Parkinson’s disease following gout: a population-based retrospective cohort study in Taiwan. BMC Neurol. 2020;20:338. doi:10.1186/s12883-020-01916-9
   Web of Science ®Google Scholar
• Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson’s disease: a meta-analysis. PLoS One. 2017;12:e0173731. doi:10.1371/journal.pone.0173731
   PubMed Web of Science ®Google Scholar
• Ou R, Cao B, Wei Q, et al. Serum uric acid levels and freezing of gait in Parkinson’s disease. Neurol Sci. 2017;38:955–960. doi:10.1007/s10072-017-2871-3
   Web of Science ®Google Scholar
• Shi X, Zheng J, Ma J, et al. Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson’s disease. Neurol Sci. 2022;43:1474–1754. doi:10.1007/s10072-021-05558-8
   Web of Science ®Google Scholar
• Sheu JJ, Wang KH, Lin HC, Huang CC. Psoriasis is associated with an increased risk of parkinsonism: a population-based 5-year follow-up study. J Am Acad Dermatol. 2013;68:992–999. doi:10.1016/j.jaad.2012.12.961
   Web of Science ®Google Scholar
• Lee JH, Han K, Gee HY. The incidence rates and risk factors of Parkinson disease in patients with psoriasis: a nationwide population-based cohort study. J Am Acad Dermatol. 2020;83:1688–1695. doi:10.1016/j.jaad.2019.07.012
   Web of Science ®Google Scholar
• Li X, Sundquist J, Sundquist K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden. NDD. 2012;10:277–284.
   Google Scholar
• Rugbjerg K, Friis S, Ritz B, Schernhammer ES, Korbo L, Olsen JH. Autoimmune disease and risk for Parkinson disease: a population-based case-control study. Neurology. 2009;73:1462–1468. doi:10.1212/WNL.0b013e3181c06635
   PubMed Web of Science ®Google Scholar
• Wettermark B, Zoega H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review. Pharmacoepidemiol Drug Saf. 2013;22:691–699. doi:10.1002/pds.3457
   PubMed Web of Science ®Google Scholar
• Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106:86–94. doi:10.1111/j.1742-7843.2009.00494.x
   PubMed Web of Science ®Google Scholar
• Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40:505–515. doi:10.1177/1403494812456637
   PubMed Web of Science ®Google Scholar
• Joutsa J, Gardberg M, Roytta M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord. 2014;20:840–844. doi:10.1016/j.parkreldis.2014.04.019
   PubMed Web of Science ®Google Scholar
• Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566–576. doi:10.1212/WNL.0000000000002350
   PubMed Web of Science ®Google Scholar
• Wermuth L, Cui X, Greene N, Schernhammer E, Ritz B. Medical record review to differentiate between idiopathic Parkinson’s disease and parkinsonism: a Danish record linkage study with 10 years of follow-up. Parkinsons Dis. 2015;2015:781479. doi:10.1155/2015/781479
   Web of Science ®Google Scholar
• Harding Z, Wilkinson T, Stevenson A, et al. Identifying Parkinson’s disease and parkinsonism cases using routinely collected healthcare data: a systematic review. PLoS One. 2019;14:e0198736.
   PubMed Web of Science ®Google Scholar